Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP6 | P51161 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887176 | 0.78 | FABP6 (0.77) | FABP6GSK3BPARP10PARP11 | |
| SCHEMBL2061574 | 0.78 | FABP6 (0.54) | FABP6GSK3BALDH1A1MAPK1KDM4E | |
| SCHEMBL15525841 | 0.78 | FABP6 (0.54) | FABP6GSK3BKDM4EPARP10PARP11 | |
| SCHEMBL2994247 | 0.78 | MAOA (0.58) | FABP6GSK3BALDH1A1L3MBTL1KDM4E | |
| SCHEMBL12078170 | 0.78 | PARP10 (0.54) | FABP6GSK3BALDH1A1KDM4EHSD17B10 | |
| SCHEMBL10274616 | 0.78 | ALDH1A1 (0.56) | FABP6GSK3BALDH1A1HSD17B10GAA | |
| SCHEMBL16976359 | 0.76 | FABP6 (0.53) | FABP6GSK3BALDH1A1KDM4EHSD17B10 | |
| SCHEMBL30895911 | 0.76 | ALDH1A1 (0.57) | FABP6ALDH1A1CYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL30895870 | 0.76 | ALDH1A1 (0.57) | FABP6ALDH1A1CYP1A2CYP2C19L3MBTL1 | |
| SCHEMBL3064196 | 0.76 | AKR1A1 (0.38) | ALDH1A1MAPK1HSD17B10AKR1A1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042903-B1 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD (IN) | 2019-08-14 | — | — | EP | disclosed |
| EP-3042903-B1 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD (IN) | 2019-08-14 | — | — | EP | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| EP-2838898-B1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2017-01-18 | — | — | EP | disclosed |
| EP-2838898-B1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2017-01-18 | — | — | EP | disclosed |
| EP-3042903-A1 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | Advinus Therapeutics Limited (IN) | 2016-07-13 | — | — | EP | disclosed |
| EP-3042903-A1 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | Advinus Therapeutics Limited (IN) | 2016-07-13 | — | — | EP | disclosed |
| US-9233983-B2 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-01-12 | — | — | US | disclosed |
| US-9233983-B2 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-01-12 | — | — | US | disclosed |
| US-9233983-B2 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-01-12 | — | — | US | disclosed |
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | IMPETIS BIOSCIENCES LIMITED (IN) | 2015-03-05 | — | — | US | disclosed |
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | IMPETIS BIOSCIENCES LIMITED (IN) | 2015-03-05 | — | — | US | disclosed |
| EP-2838898-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013157022-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013157022-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | FABP6 4854/4885GSK3B 280/4885ALDH1A1 4730/4885 |
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | BTK, MALT1, LCK | FABP6 3920/4885GSK3B 8/4885ALDH1A1 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.